The Science of Certainty

Gubra enables you to progress your preclinical pharmacology development for metabolic disorders with more certainty than any other research partner. We offer highly specialized services within five main disease areas.


Benefit from our extensive know-how in NASH and test your compound in our validated DIO NASH mouse models.

Learn more

Kidney (CKD)


Check out our novel rodent models of diabetic nephropathy.

Learn more

Heart (CVD)


Check out our novel rodent models of cardiovascular disease.

Learn more


Qualify and advance your assessment of novel compounds to treat type 2 diabetes and diabetic complications.

Learn more


Tap into our vast scientific experience with diet-induced obesity (DIO) models and other commercially available models.

Learn more

Gubra response measures to corona virus/covid-19

During the global coronavirus outbreak, Gubra’s key priority is to help the authorities in limiting spread of disease and protect our employees and their families, while at the same time safeguard a continued supply of research services to our partners and customers. The situation is continually evolving, but currently we are not experiencing any constraints and our study activities are running according to plans.

We have worked out detailed contingency plans for situations like this including inventory and staffing policy/plans that serves to maintain a continuity in deliveries.

3D imaging of neurons

Light-sheet fluorescence microscopy allows for 3D imaging, mapping and quantification of neurons at single cell resolution throughout the entire, intact mouse brain.

In animal models of Parkinson Disease (PD) estimation of dopaminergic neuron numbers and projections are imperative for model phenotyping and assessment of drug treatment effects.

Upcoming Events

27 October 2020 Webinar: 'Imaging diabetes using light sheet microscopy' with Gubra scientist and 3D imaging expert Jacob Hecksher-Sørensen.
10 November 2020 Webinar: 'Lost in translation – how to improve the translatability of rodent models of diabetic kidney disease' with Gubra Scientist Mette and kidney expert Mette Viberg Østergaard.
November 13-16 AASLD - The Liver Meeting (virtual conference)
See all events


+ 29 June 2020 At Gubra, we have accomplished a robust investment solution for all our employees by intentionally opting for a sustainable pension scheme (AP Bæredygtig). Read more
+ 26 May 2020 In the company’s first CSR Report for 2019, Gubra sets a new standard for simple and comparable CSR reporting. Read more
See all news

Neurodegenerative diseases
– a customized service

With a strong academic background in neuroscience and neurostereology we have conducted several preclinical studies of neurodegenerative diseases, including Parkinson and Alzheimers Disease.

Do you want to be part of a great team aiming high? Join us.

Our ambition is that Gubra is a place where talented people are empowered to put their competencies and passion into play every day. We work as a team to make a difference for people with serious metabolic diseases.